Navigation Links
Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
Date:3/4/2013

Toronto, Canada (PRWEB) March 04, 2013

With the advent of direct acting antiviral agents for the Hepatitis C virus (HCV), there has been a concerted effort to offer broad testing services and capabilities to assist clients at every stage of drug development. From lead compound optimization and resistance profiling to Phase IV marketing studies, LabCorp and its specialty testing laboratories offer specialized, proprietary testing. In fact, LabCorp offers global central laboratory testing services to support HCV trials around the world.

In this webinar, a thorough overview of currently available HCV capabilities will be presented, including:

  •     Technical overview of HCV assay services, including resistance testing (mutation detection and replicon-based DAA susceptibility assays), viral load assays, genotype/subtype characterization and IL28B allele testing
  •     Appropriate timing and circumstances for each specific test
  •     How these assays can be used to support regulatory filings
  •     How LabCorp’s global reach can help clients conduct more cost-effective clinical trials

The presentation will also highlight ongoing and future HCV assay development activities, such as the implementation of next generation sequencing platforms and the expanded presence in China, Southeast Asia and Europe.

For more information about this event or to register, visit: http://xtks.in/xto575-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10472827.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CNIO researchers take part in the most comprehensive personalized medicine study performed to date
2. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
3. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
4. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
5. CIVCO to Present Comprehensive Motion Management Solutions at ASTRO 2012 Booth #10003
6. Dr. Ross Kaplan Offers New Comprehensive Acne Package Treatment for Acne and Acne Scarring
7. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
8. Rigaku introduces the world’s most comprehensive biological SAXS system for the home lab
9. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):